FDA Mandates Black Box Warning for Uloric®, Now Linked to Heart Attack, Stroke and Death.
If you have been prescribed Uloric to treat gout, there may be an increased risk of suffering a heart-related illness or death while taking the medication. You may be eligible to pursue legal action. Call 410.649.2000 or use the form below.
Uloric, also called febuxostat, is a medication that was approved by the FDA to treat gout, a form of arthritis. In February 2019, the U.S. Food and Drug Administration stated that there is a higher risk of death associated with gout medicine Uloric (febuxostat), as compared to other gout medicines. The FDA has now mandated a Black Box Warning for Uloric as a result of those findings.
How Can The Law Offices Of Peter Angelos Help You?
Our firm has provided our support and legal representation to individuals and families for more than 60 years. Our legal team has recovered billions of dollars in compensation on behalf of injured victims across the country, and is passionate about protecting the rights of those we serve. With decades of combined experience, extensive resources, and a talented team of attorneys, we are prepared to handle even the most challenging pharmaceutical liability cases.
What is Uloric®?
Uloric, also called febuxostat, is a medication that was approved in 2009 to treat gout, a form of arthritis. Gout is a chronic disease that occurs in patients as a result of uric acid buildup that leads to severe swelling and pain in the joints. The condition impacts over eight million individuals in the United States. Uloric works to lower the amount of uric acid in the body and provide relief for patients suffering from gout.
FDA Evaluates the Link Between Uloric and Heart-Related Death in 2017
In November 2017, the FDA began to evaluate the link between Uloric and death, specifically death associated with the heart. After extensive evaluation, the FDA concluded that there is a higher risk of heart-related death associated with Uloric compared to other types of gout medication such as allopurinol. The FDA came to this conclusion after a review of the results of a clinical trial that found a higher risk of heart-related death, as well as death from all causes, with Uloric.